Featured Research

from universities, journals, and other organizations

High-dose Therapy For Liver Disease Not Effective, Study Suggests

Date:
August 31, 2009
Source:
Mayo Clinic
Summary:
Scientists have found that a common treatment for primary sclerosing cholangitis, a chronic liver disease, is not helpful for patients.

A national team of researchers led by scientists at Mayo Clinic has found that a common treatment for primary sclerosing cholangitis, a chronic liver disease, is not helpful for patients, according to a study published this month in the journal Hepatology.

Primary sclerosing cholangitis (PSC) is a disease of the bile ducts. In this case, the term "cholangitis" refers to inflammation of the bile ducts, while "sclerosing" describes the hardening and scarring of the bile ducts that result from chronic inflammation.

"Primary sclerosing cholangitis is a serious liver disease lacking an effective medical therapy," says Keith Lindor, M.D., Mayo Clinic gastroenterologist and the study's lead researcher. "Some studies have shown that the use of ursodeoxycholic acid, a naturally occurring bile acid, may be a potential solution for patients. Our research, however, showed long-term use of this treatment in high dosages is not suitable for patients."

In this six-year, multicenter trial, 150 patients were enrolled in the study to determine the effectiveness of ursodeoxycholic acid (UDCA) in treatment of PSC. Seventy-six patients were treated with higher doses (28 to 30 mg/kg/day) of UDCA and 74 patients were given a placebo. Serious adverse events were more common in the UDCA group than the placebo group, which prompted researchers to halt the study. UDCA has been thought to be a possible treatment solution for PSC patients, but this trial indicates that the drug, used at this higher dose, is not helpful.

"All of us were surprised that the higher doses of UDCA did not help; in fact, the risk of developing even more liver problems increased with the higher dosages," says Dr. Lindor. "While this was thought to be the best potential treatment for PSC, our study found that not to be the case."

Dr. Lindor says that patients who are currently on higher doses of UDCA should consult with their doctors. He also points out that these study findings highlight the need for more research to look into better treatment options for PSC.

PSC is a progressive disease that leads to liver damage and, eventually, liver failure. Liver transplant is the only known cure for PSC, but transplant is typically reserved for people with severe liver damage.

PSC most often affects people in their 30s to 50s. The average age at diagnosis is 40. However, the condition can arise in childhood. About 60 to 75 percent of people diagnosed with the disease are men. Approximately 70 percent of people with PSC have an associated disease such as inflammatory bowel disease, osteoporosis, gallbladder disease and bile duct cancer or cholangiocarcinoma. However, only 1 to 5 percent of people with inflammatory bowel disease have PSC.

Other members of the Mayo Clinic research team include M. Edwyn Harrison, M.D., Denise Harnois, D.O., Roberta Jorgensen, Jan Petz, Jill Keach, Julie Braaten, M.D., Ellen Miceli, Jeff Schmoll, Tanya Hoskin, Prabin Thapa and Felicity Enders, Ph.D. Other researchers include Kris Kowdley, M.D., and Jody Mooney, M.D., Virginia Mason Medical Center; Velimir Luketic, M.D., and Carol Sargeant, M.D., Virginia Commonwealth University School of Medicine; Timothy McCashland, M.D., and Tamara Bernard, M.D., University of Nebraska; and Alex Befeler, M.D., and Debra King, M.D., Saint Louis University.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. Keith D. Lindor, Kris V. Kowdley, Velimir A. C. Luketic, M. Edwyn Harrison, Timothy McCashland, Alex S. Befeler, Denise Harnois, Roberta Jorgensen, Jan Petz, Jill Keach, Jody Mooney, Carol Sargeant, Julie Braaten, Tamara Bernard, Debra King, Ellen Miceli, Jeff Schmoll, Tanya Hoskin, Prabin Thapa, Felicity Enders. High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis. Hepatology, 2009 DOI: 10.1002/hep.23082

Cite This Page:

Mayo Clinic. "High-dose Therapy For Liver Disease Not Effective, Study Suggests." ScienceDaily. ScienceDaily, 31 August 2009. <www.sciencedaily.com/releases/2009/08/090819110025.htm>.
Mayo Clinic. (2009, August 31). High-dose Therapy For Liver Disease Not Effective, Study Suggests. ScienceDaily. Retrieved August 29, 2014 from www.sciencedaily.com/releases/2009/08/090819110025.htm
Mayo Clinic. "High-dose Therapy For Liver Disease Not Effective, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/08/090819110025.htm (accessed August 29, 2014).

Share This




More Health & Medicine News

Friday, August 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Killer Amoeba Found in Louisiana Water System

Killer Amoeba Found in Louisiana Water System

AP (Aug. 28, 2014) State health officials say testing has confirmed the presence of a killer amoeba in a water system serving three St. John the Baptist Parish towns. (Aug. 28) Video provided by AP
Powered by NewsLook.com
Who Could Be Burnt by WHO's E-Cigs Move?

Who Could Be Burnt by WHO's E-Cigs Move?

Reuters - Business Video Online (Aug. 28, 2014) The World Health Organisation has called for the regulation of electronic cigarettes as both tobacco and medical products. Ciara Lee looks at the impact of the move on the tobacco industry. Video provided by Reuters
Powered by NewsLook.com
CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

Newsy (Aug. 28, 2014) CDC director Tom Frieden says the Ebola outbreak is even worse than he feared. But he also said there's still hope to contain it. Video provided by Newsy
Powered by NewsLook.com
How A 'Rule Of Thumb' Could Slow Down Drinking

How A 'Rule Of Thumb' Could Slow Down Drinking

Newsy (Aug. 28, 2014) A study suggests people who follow a "rule of thumb" when pouring wine dispense less than those who don't have a particular amount in mind. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins